This has set the highest record of private equity for biotechnology companies.
Recently, Nasdaq-listed pharmaceutical company “Blackstone Life Sciences” announced that it has partnered with RNAi Therapy ” Alnylam “ reached a broad strategic partnership. In the cooperation agreement, Blackstone will provide $ 2 billion in funding, led by Blackstone Life Sciences and Blackstone’s credit platform GSO Capital Partners, to help Alnylam promote technological innovation and accelerate the commercialization process.
This strategic cooperation of up to 2 billion US dollars has created the highest record of private placement for biotechnology companies.
It is reported that this round of investment is intended to help Alnylam “achieve financial sustainability without refinancing.”
Why is this strategic investment worth paying attention to? Alnylam’s area of strength is RNAi (RNA interference). In 2006, the discovery of this mechanism reached the Nobel Prize in Physiology or Medicine. Today, RNAi is also regarded as a cutting-edge RNA therapy with great potential.
picture from Alnylam ’s official website
RNAi is a natural gene silencing phenomenon, Alnylam is transforming RNAi into new Innovative drugs are mainly used to treat these four types of diseases: cardiometabolic diseases, liver infectious diseases, central nervous system (CNS) and eye diseases.
As a leader in the industry, Alnylam ’s commercialization process is fast, and several products have been launched on the market, including the RNAi therapeutic product ONPATTRO (patisiran). Obtained by the European Union, Canada, Japan and SwitzerlandApproved, its listing has opened the second wave of small nucleic acid drugs; and GIVLAARI (givosiran) approved in the United States and the European Union. In terms of drug research, Alnylam has six candidate products that have reached the advanced stage.
Market interest in RNAi is high, and this new treatment is very promising. The track has attracted numerous pharmaceutical companies and millions of dollars of capital have poured in. In the early history of Alnylam, it had faced many challenges, the company ’s relationship with its main partners was dissolved, which caused internal confusion lose confidence. After overcoming the difficulties, the company has built an in-depth RNAi therapy pipeline system.